Planned Sale Of China’s Cedara Medical Software Firm Canceled
This article was originally published in PharmAsia News
U.S.-based Merge Healthcare has canceled plans to sell its Chinese subsidiary, Cedara Software Shanghai to Inqgen Technology of Taiwan. Merge, which produces medical-imaging software for drug and device makers, has changed management since the sale was announced nearly a year ago. The new executives consider China as a major factor in the growth planned for its core business, an official said. He said Cedara would enable Merge to have sales, marketing, customer support and engineering presences in China, potentially the world's largest market for its products. (Click here for more
You may also be interested in...
One effect of Brexit is that the UK’s National Institute for Biological Standards and Control will have additional responsibilities from next year in terms of the independent batch testing and release of products such as vaccines and medicines derived from human blood and plasma in Great Britain.
Sun Pharma and its US Taro subsidiary have further criticized a recent CMS policy proposal that would see Medicare Part B drugs approved under the US hybrid 505(b)(2) pathway reimbursed at a lower rate applicable to multiple source products.
An advanced immunotherapy for recurrent glioblastoma and the first biosimilar version of Lucentis for age-related macular degeneration have also been submitted for review by the European Medicines Agency for potential pan-EU authorization.